Calling All Health Tech and AI Innovators!

Explore the forefront of intellectual property in the age of AI. This seminar addresses the challenges and strategies for protecting digital health innovations in the United States. The rapid convergence of AI and ML with life sciences has reshaped healthcare, moving it towards a personalized, data-driven model. Don't miss this opportunity to learn from a leading expert in the field.

Gain Crucial Insights On: Strategic approaches for developing a resilient IP portfolio that can withstand Section 101 scrutiny. Practical guidance on identifying and framing invention-worthy contributions in this dynamic sector. A case study illustrating how robust IP protection and data rights enhanced the commercial success and long-term value of a digital health solution.

– Event Details –

Date: September 11, 2025 (Thursday)
Time: 16:00 – 17:30
Venue: 1/F – KB132, Knowles Building, Main Campus


Don't Miss Out – Register Today! – All staff, students, and members of the public interested in digital health, AI/ML, and intellectual property are welcome.


– Meet Our Speaker –

Mr Roger Kuan
Partner
US Head of Digital Health and Precision Medicine Practice
Norton Rose Fulbright US LLP

Roger leads the U.S. Digital Health and Precision Medicine Practice at Norton Rose Fulbright, advising digital health companies and research institutions on intellectual property (IP), data rights, and regulatory compliance.

His expertise covers comprehensive IP strategy and portfolio management, including patents, trademarks, copyrights, and trade dress. He also provides strategic counsel on data rights, licensing, freedom-to-operate analyses, monetization, dispute resolution, and IP due diligence. Roger focuses on the life sciences sector, assisting clients with research tools, diagnostics, medical devices, analytical software, digital therapeutics, and biomanufacturing platforms.

Roger specializes in emerging technologies, including precision medicine (genomic sequencing, AI/ML, computational genomics, molecular diagnostics, companion diagnostics), digital health solutions (mobile apps, clinical decision support, imaging diagnostics, wearables, software), and 3D printing/bioprinting.

Before joining Norton Rose Fulbright, Roger was Director and IP Counsel at Thermo Fisher Scientific, leading global IP strategy for molecular diagnostics, bioproduction, nucleic acid sequencing, and life sciences tools.

Roger was recognized by Lawdragon in 2005 as one of the "500 Leading Global IP Lawyers." He has been recommended by the Legal 500 for intellectual property in 2019, 2024, and 2025, and was named a leading IP lawyer by IAM Patent 1000 in 2024 and 2025.